Pipeline
Q-Sphera™
ID | API | Therapeutic Area | Administration | Formulation | Preclinical | PHI | PHII | Partnering Status |
---|---|---|---|---|---|---|---|---|
MTD211 | Small molecule | CNS | Long Acting Injectable | |||||
Indication: Schizophrenia, Major Depressive Disorder |
||||||||
MTD219 | Small molecule | Anti-rejection | Long Acting Injectable | |||||
Indication: Immunosuppression in organ transplant recipients |
||||||||
MTD220 | Monoclonal Antibody | Undisclosed | Long acting Injectable | |||||
Investigational programme for the encapsulation of Monoclonal Antibodies Midatech Pharma are applying Q-Sphera technology to the encapsulation of therapeutic proteins, including monoclonal antibodies. |
||||||||
External: MTX212 | undisclosed | undisclosed | undisclosed | Partnered | ||||
External: MTX213 | undisclosed | undisclosed | undisclosed | Partnered | ||||
External: MTX214 | undisclosed | undisclosed | undisclosed | Partnered | ||||
External: MTX216 | undisclosed | undisclosed | undisclosed | Partnered | ||||
MTD201 | Octreotide | Endocrine disorder | Long acting injectable | |||||
Indication: Carcinoid cancer and Acromegaly |
MidaSolve
ID | API | Therapeutic Area | Administration | Formulation | Preclinical | PHI | PHII | Partnering Status |
---|---|---|---|---|---|---|---|---|
MTX110 | Panobinostat | Glioblastoma | Direct to tumour via CED | |||||
MTX110 | Panobinostat | Brain Cancer in Children (DIPG) | Direct to tumour via CED | |||||
MTX110 | Panobinostat | Medulloblastoma | Direct to tumour | |||||
MTX110 is a water‐soluble formulation of panobinostat that enables delivery at chemotherapeutic doses directly to the site of the tumour. The currently available oral formulation of panobinostat lactate is not suitable for treatment of brain cancers owing to poor blood‐brain barrier penetration and inadequate brain drug concentrations. MTX110 is delivered directly into and around the patient's tumour via a catheter system (e.g. CED or fourth ventricle infusions) to bypass the blood‐brain barrier. This technique exposes the tumour to very high drug concentrations while simultaneously minimising systemic drug levels and the potential for toxicity and other side effects. |
MidaCore™
ID | API | Therapeutic Area | Administration | Formulation | Preclinical | PHI | PHII | Partnering Status |
---|---|---|---|---|---|---|---|---|
MTX114 | Methotrexate | Skin disorders | Topical | |||||
Indication: Psoriasis, Atopic dermatitis MTX114 is the first gold nanoparticle formulation of methotrexate. Through complexing with Midacore gold nanoparticle technology, MTX114 delivers enhanced efficacy over methotrexate alone. Topical delivery minimises systemic exposure reducing the risk of toxicities associated with systemic administration of methotrexate, providing a superior treatment option to patients with mild to moderate psoriasis. |